SIGA Technologies reported Q3 2024 revenues of $10.0 million, including $8.9 million from product sales and supportive services, primarily driven by $8.1 million in oral TPOXX sales to the U.S. Government and $0.8 million in international sales. The company posted net income of $1.3 million or $0.02 per share, compared to a net loss of $0.4 million in Q3 2023. Operating income was $0.5 million, reflecting improved operational efficiency.For the nine months ended September 30, 2024, total revenues reached $57.3 million, with $53.5 million from product sales including $40.4 million to the U.S. Government, $11.8 million in international sales, and $1.1 million to the Department of Defense. The company maintained a strong cash position of $99.3 million as of September 30, 2024, despite paying a special dividend of approximately $42.7 million during the period.Research and development expenses decreased to $3.0 million in Q3 2024 from $3.6 million in Q3 2023, primarily due to lower vendor-related expenses following the completion of certain PEP Label Expansion Program activities. The company continues to advance its clinical programs, including potential label expansions for TPOXX, with a targeted FDA supplemental New Drug Application filing for smallpox post-exposure prophylaxis in Q3 2025.

SIGA Technologies reported Q3 2024 revenues of $10.0 million, including $8.9 million from product sales and supportive services, primarily driven by $8.1 million in oral TPOXX sales to the U.S. Government and $0.8 million in international sales. The company posted net income of $1.3 million or $0.02 per share, compared to a net loss of $0.4 million in Q3 2023. Operating income was $0.5 million, reflecting improved operational efficiency.For the nine months ended September 30, 2024, total revenues reached $57.3 million, with $53.5 million from product sales including $40.4 million to the U.S. Government, $11.8 million in international sales, and $1.1 million to the Department of Defense. The company maintained a strong cash position of $99.3 million as of September 30, 2024, despite paying a special dividend of approximately $42.7 million during the period.Research and development expenses decreased to $3.0 million in Q3 2024 from $3.6 million in Q3 2023, primarily due to lower vendor-related expenses following the completion of certain PEP Label Expansion Program activities. The company continues to advance its clinical programs, including potential label expansions for TPOXX, with a targeted FDA supplemental New Drug Application filing for smallpox post-exposure prophylaxis in Q3 2025.